Literature DB >> 30518233

Fermented Red Ginseng Alleviates Cyclophosphamide-Induced Immunosuppression and 2,4,6-Trinitrobenzenesulfonic Acid-Induced Colitis in Mice by Regulating Macrophage Activation and T Cell Differentiation.

Jeon-Kyung Kim1, Jae-Young Kim1, Se-Eun Jang1,2, Min-Sun Choi2, Hyo-Min Jang1, Hae-Hyun Yoo2, Dong-Hyun Kim1.   

Abstract

A variety of products have been developed with red ginseng (RG, the steamed roots of Panax ginseng Meyer). To clarify the immunomodulating effects of water-extracted RG (wRG), 50% ethanol-extracted RG (eRG), enzyme-treated eRG (ERG) and probiotic-fermented eRG (FRG), we examined their immunopotentiating and immunosuppressive effects in mice with cyclophosphamide (CP)-induced immunosuppression (CI) or 2,4,6-trinitrobenzenesulfonic acid (TNBS)-induced colitis (TC). Oral administration of RG in CI mice significantly increased blood IFN- γ levels. Treatment with RG also increased the tumoricidal effects of CI mouse splenic cytotoxic T (Tc) and NK cells against YAC-1 cells. Treatment with RGs, in particular FRG and wRG, significantly increased Th1 cell differentiation. Treatment with RG except wRG increased Treg cell differentiation. However, wRG alone increased IL-6 and IL-17 expression in the colon of CI mice. Furthermore, RG alleviated colitis in TC mice. FRG most potently suppressed TNBS-induced colon shortening, NF- κ B activation and TNF- α and IL-17 expression and increased IL-10 expression. RGs inhibited TNF- α expression and increased IL-10 expression in lipopolysaccharide-stimulated primary macrophages in vitro while the differentiation of splenic T cells into type 1 T (Th1) and regulatory T (Treg) cells was increased by FRG in vitro. In conclusion, FRG can alleviate immunosuppression and inflammation by inhibiting macrophage activation and regulating Th1 and Treg cell differentiation.

Entities:  

Keywords:  Immunomodulation; Immunosuppression; Inflammation; Probiotic-Fermented Red Ginseng

Mesh:

Substances:

Year:  2018        PMID: 30518233     DOI: 10.1142/S0192415X18500945

Source DB:  PubMed          Journal:  Am J Chin Med        ISSN: 0192-415X            Impact factor:   4.667


  7 in total

1.  Effects of gut microbiota on the pharmacokinetics of protopanaxadiol ginsenosides Rd, Rg3, F2, and compound K in healthy volunteers treated orally with red ginseng.

Authors:  Jeon-Kyung Kim; Min Sun Choi; Woonhee Jeung; Jehyeon Ra; Hye Hyun Yoo; Dong-Hyun Kim
Journal:  J Ginseng Res       Date:  2019-06-05       Impact factor: 6.060

2.  Inhibition of Programmed Death Receptor-1/Programmed Death Ligand-1 Interactions by Ginsenoside Metabolites.

Authors:  Nam-Hui Yim; Young Soo Kim; Hwan-Suck Chung
Journal:  Molecules       Date:  2020-04-29       Impact factor: 4.411

Review 3.  Effects of Red and Fermented Ginseng and Ginsenosides on Allergic Disorders.

Authors:  Myung Joo Han; Dong-Hyun Kim
Journal:  Biomolecules       Date:  2020-04-20

4.  Fermented red ginseng and ginsenoside Rd alleviate ovalbumin-induced allergic rhinitis in mice by suppressing IgE, interleukin-4, and interleukin-5 expression.

Authors:  Hye In Kim; Jeon-Kyung Kim; Jae-Young Kim; Myung Joo Han; Dong-Hyun Kim
Journal:  J Ginseng Res       Date:  2019-03-07       Impact factor: 6.060

5.  SBT (Composed of Panax ginseng and Aconitum carmichaeli) and Stigmasterol Enhances Nitric Oxide Production and Exerts Curative Properties as a Potential Anti-Oxidant and Immunity-Enhancing Agent.

Authors:  Na-Ra Han; Kyeoung-Cheol Kim; Ju-Sung Kim; Hi-Joon Park; Seong-Gyu Ko; Phil-Dong Moon
Journal:  Antioxidants (Basel)       Date:  2022-01-20

6.  Bifidobacteria-Fermented Red Ginseng and Its Constituents Ginsenoside Rd and Protopanaxatriol Alleviate Anxiety/Depression in Mice by the Amelioration of Gut Dysbiosis.

Authors:  Sang-Kap Han; Min-Kyung Joo; Jeon-Kyung Kim; Woonhee Jeung; Heerim Kang; Dong-Hyun Kim
Journal:  Nutrients       Date:  2020-03-26       Impact factor: 5.717

Review 7.  Natural Anti-Inflammatory Compounds as Drug Candidates for Inflammatory Bowel Disease.

Authors:  Linshan Duan; Shuyu Cheng; Long Li; Yanling Liu; Dan Wang; Guoyan Liu
Journal:  Front Pharmacol       Date:  2021-07-14       Impact factor: 5.810

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.